Donanemab in Early Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease. METHODS: ), the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living Inventory (ADCS-iADL), and the Mini-Mental State Examination (MMSE), as well as the change in the amyloid and tau burden on PET. RESULTS: A total of 257 patients were enrolled; 131 were assigned to receive donanemab and 126 to receive placebo. The baseline iADRS score was 106 in both groups. The change from baseline in the iADRS score at 76 weeks was -6.86 with donanemab and -10.06 with placebo (difference, 3.20; 95% confidence interval, 0.12 to 6.27; P = 0.04). The results for most secondary outcomes showed no substantial difference. At 76 weeks, the reductions in the amyloid plaque level and the global tau load were 85.06 centiloids and 0.01 greater, respectively, with donanemab than with placebo. Amyloid-related cerebral edema or effusions (mostly asymptomatic) occurred with donanemab. CONCLUSIONS: In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo at 76 weeks, although results for secondary outcomes were mixed. Longer and larger trials are necessary to study the efficacy and safety of donanemab in Alzheimer's disease. (Funded by Eli Lilly; TRAILBLAZER-ALZ ClinicalTrials.gov number, NCT03367403.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The phase 3 trial of donanemab, monoclonal antibody that target Aβ plaques, fibrils, soluble protofibrils, and oligomeric Aβ species all targeting A β plaques, required p eople with early AD to have both positive amyloid PET and tau-PET, further dividing participants into low and intermediate/high positive tau burden groups.(464)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [464]
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“These interventions have demonstrated a modest capacity to reduce cognitive decline in select patient subgroups, but are associated with the risk of side effects, including brain swelling and microhemorrhages.”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“The first therapies for AD targeting the removal of amyloid are now being approved with modest positive outcomes, although associated with several side effects (Sims et al. 2023; Mintun et al. 2021; Van Dyck et al. 2023).”
From Alzheimer's Protection by PLCγ2 Compacts Plaques, Redistributes Microglia, and Protects Synapses in App NL ‐G‐F Mice (2026) · cites this paper as Mintun et al. 2021
In the citing paper
“One response to these problems has been the design of clinical instruments that purport to be able to reveal treatment effects with greater sensitivity: for example, the iADRS 83 or the preclinical Alzheimer cognitive composite 96 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [83]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Self-citationThe antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Self-citationTwo Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Synergy between amyloid-β and tau in Alzheimer’s disease
Busche, M. A., & Hyman, B. T. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0687-6 · Cited by 1,242
Cited by
Items 101–200 of 1,008
Treatments for Alzheimer's disease emerge
Selkoe, D. J. (2021) · Science · doi:10.1126/science.abi6401 · Cited by 117
Lowe, S. L., Duggan Evans, C., Shcherbinin, S., Cheng, Y.-J., Willis, B. A., Gueorguieva, I., Lo, A. C., Fleisher, A. S., Dage, J. L., Ardayfio, P., et al. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.56 · Cited by 115
Self-citationMonteiro, C., Tóth, B. I., Brunstein, F., Bobbala, A., Datta, S., Ceniceros, R., Bohorquez, S. M. S., Anania, V. G., Wildsmith, K. R., Schauer, S. P., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207663 · Cited by 124
Self-citationAducanumab Therapy to Treat Alzheimer’s Disease: A Narrative Review
Beshir, S. A., Aadithsoorya, A. M., Parveen, A., Goh, S. S. L., Hussain, N., & Menon, V. B. (2022) · International Journal of Alzheimer's Disease · doi:10.1155/2022/9343514 · Cited by 115
“Another agent donanemab has demonstrated an improvement in composite cognition scores and ability to do activities of daily living (ADLs) in patients with early AD [55].”
BackgroundThe role of the immune system in Alzheimer’s disease
Wu, K., Zhang, Y.-R., Huang, Y., Dong, Q., Tan, L., & Yu, J. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101409 · Cited by 127
The need to show minimum clinically important differences in Alzheimer's disease trials
Liu, K. Y., Schneider, L. S., & Howard, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00197-8 · Cited by 113
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Honig, L. S., Barakos, J., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M., Kramer, L. D., Swanson, C. J., & Sabbagh, M. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12377 · Cited by 112
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13449 · Cited by 113
Edwards, A. L., Collins, J. A., Junge, C., Kordasiewicz, H., Mignon, L., Wu, S., Li, Y., Lin, L., DuBois, J., Hutchison, R. M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3861 · Cited by 113
Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology
Ramanan, V. K., Armstrong, M. J., Choudhury, P., Coerver, K. A., Hamilton, R. H., Klein, B. C., Wolk, D. A., Wessels, S. R., & Jones, L. K. (2023) · Neurology · doi:10.1212/wnl.0000000000207757 · Cited by 133
Rezai, A. R., Ranjan, M., Haut, M. W., Carpenter, J., D’Haese, P.-F., Mehta, R. I., Najib, U., Wang, P., Claassen, D. O., Chazen, J. L., et al. (2023) · Journal of Neurosurgery · doi:10.3171/2022.9.jns221565 · Cited by 111
An, J., Kim, K., Lim, H. J., Kim, H. Y., Shin, J. W., Park, I., Cho, I., Kim, H. Y., Kim, S., McLean, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44818-x · Cited by 125
Chong, J. R., Ashton, N. J., Karikari, T. K., Tanaka, T., Schöll, M., Zetterberg, H., Blennow, K., Chen, C., & Lai, M. K. P. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327370 · Cited by 115
“11 An example of such a trial is a phase II clinical study of BAN2401 (also called lecanemab) in early AD subjects with positive biomarkers for brain amyloid pathology.”
BackgroundPerspectives and challenges in patient stratification in Alzheimer’s disease
Abdelnour, C., Agosta, F., Bozzali, M., Fougère, B., Iwata, A., Nilforooshan, R., Takada, L. T., Viñuela, F., & Traber, M. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01055-y · Cited by 108
“This resulted in a decrease in the variable trajectories of clinical decline [44].”
BackgroundAnti‐amyloid antibody treatments for Alzheimer's disease
Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C. (2024) · European Journal of Neurology · doi:10.1111/ene.16049 · Cited by 106
“In a phase 2 clinical trial, donanemab reduced A β plaques in the brain and showed a statistically significant slowing of cognitive decline in patients with early AD [25].”
BackgroundCopper homeostasis and neurodegenerative diseases
Wang, Y., Li, D., Xu, K., Wang, G., & Zhang, F. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00642 · Cited by 122
Health Benefits, Food Applications, and Sustainability of Microalgae-Derived N-3 PUFA
Liu, Y., Ren, X., Fan, C., Wu, W., Zhang, W., & Wang, Y. (2022) · Foods · doi:10.3390/foods11131883 · Cited by 103
“This neurodegeneration process is very sophisticated and involves many potential mechanisms in which an effective cure with a single therapeutic agent has yet to be found [52,66].”
BackgroundCan we learn lessons from the FDA's approval of aducanumab?
Liu, K. Y., & Howard, R. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00557-x · Cited by 104
Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 111
“Furthermore, Elli Lilly, based on results from a phase II study [32], recently announced their intention to apply to FDA for an “accelerated approval” of donanemab (https://www.”
BackgroundInfluentialGroot, C., Cicognola, C., Bali, D., Triana-Baltzer, G., Dage, J. L., Pontecorvo, M. J., Kolb, H. C., Ossenkoppele, R., Janelidze, S., & Hansson, O. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01005-8 · Cited by 99
“In extension, our findings suggest that treatment effect monitoring, as was recently published for the plasma p-tau217Lilly assay in the TRAILBLAZER-ALZ (Donanemab) trial [5, 33], could also be achieved with the novel plasma p-tau217+Janssen assay.”
MethodAmyloid-Related Imaging Abnormalities: An Update
Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99
CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
Horie, K., Barthélemy, N. R., Spina, S., VandeVrede, L., He, Y., Paterson, R. W., Wright, B. A., Day, G. S., Davis, A. A., Karch, C. M., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02075-9 · Cited by 97
Taylor, X., Clark, I. M., Fitzgerald, G. J., Oluoch, H., Hole, J. T., DeMattos, R. B., Wang, Y., & Pan, F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00649-w · Cited by 94
Cogswell, P. M., Andrews, T. J., Barakos, J. A., Barkhof, F., Bash, S., Benayoun, M. D., Chiang, G. C., Franceschi, A. M., Jack, C. R., Pillai, J. J., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8469 · Cited by 93
Kuzu, O. F., Granerud, L. J. T., & Saatcioglu, F. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02439-w · Cited by 144
Ma, D., Martin, B. S., Gallagher, K. S., Saito, T., & Dai, M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08626 · Cited by 96
Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
Bayer, T. A. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 94
“2 trial evaluated safety, tolerability and efficacy of passive immunization with donanemab a plaque-specific humanized antibody against AβpE3-X [73].”
BackgroundLesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Passive anti-amyloid β immunotherapy in Alzheimer's disease—opportunities and challenges
Heneka, M. T., Morgan, D., & Jessen, F. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01883-x · Cited by 123
Expectations and clinical meaningfulness of randomized controlled trials
Petersen, R. C., Aisen, P. S., Andrews, J. S., Atri, A., Matthews, B. R., Rentz, D. M., Siemers, E. R., Weber, C. J., & Carrillo, M. C. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12959 · Cited by 95
“10,27 For example, estimating a 25% slowing of progression in the treatment group, at 12 months a 0.5-point difference between the treatment and placebo groups shows the decline in the treatment group delayed for 3 months (i.e., a slowing of decline or disease progression of 3 months).”
BackgroundInfluentialApplication of Bayesian approaches in drug development: starting a virtuous cycle
Ruberg, S. J., Beckers, F., Hemmings, R., Honig, P. K., Irony, T., LaVange, L. M., Liebérman, G., Mayne, J. T., & Moscicki, R. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00638-0 · Cited by 112
“Initially, a Bayesian analysis may be a supplemental description of the trial results, as in the case of a phase II trial for the potential Alzheimer disease therapy donanemab 46 .”
MethodGenomics of Alzheimer’s disease implicates the innate and adaptive immune systems
Li, Y., Laws, S. M., Miles, L. A., Wiley, J. S., Huang, X., Masters, C. L., & Gu, B. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03986-5 · Cited by 111
Anti-inflammatory clearance of amyloid-β by a chimeric Gas6 fusion protein
Jung, H., Lee, S. Y., Lim, S., Choi, H. R., Choi, Y., Kim, M., Kim, S., Lee, Y., Han, K. H., Chung, W., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01926-9 · Cited by 94
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 125
Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer’s disease
Tanner, J. A., Iaccarino, L., Edwards, L., Asken, B. M., Gorno-Tempini, M. L., Kramer, J. H., Pham, J., Perry, D. C., Possin, K., Malpetti, M., et al. (2022) · Brain · doi:10.1093/brain/awac229 · Cited by 91
Donanemab for Alzheimer’s Disease: A Systematic Review of Clinical Trials
Rashad, A., Rasool, A., Shaheryar, M., Sarfraz, A., Sarfraz, Z., Robles-Velasco, K., & Cherrez-Ojeda, I. (2022) · Healthcare · doi:10.3390/healthcare11010032 · Cited by 91
“Molecularly, AD has two pathological hallmarks in the central nervous system (CNS), extracellular amyloid plaques derived from amyloid-β peptides and the formation of neurofibrillary tangles consisting of aggregated and hyperphosphorylated tau [9,10].”
BackgroundInfluentialApolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
“Current therapeutic strategies targeting amyloid plaque removal have led to the FDA-approval of three anti-body-based drugs that achieved a robust reduction in amyloid plaque load in the brain but the benefits on cognitive decline are modest and there are concerns about their safety [241, 242].”
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Young, C. B., Winer, J. R., Younes, K., Cody, K. A., Betthauser, T. J., Johnson, S. C., Schultz, A., Sperling, R. A., Greicius, M. D., Cobos, I., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.0676 · Cited by 79
Self-citationVillain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Critical Appraisal of Amyloid Lowering Agents in AD
Decourt, B., Boumelhem, F., Pope, E. D., Shi, J., Mari, Z., & Sabbagh, M. N. (2021) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-021-01125-y · Cited by 85
Gueorguieva, I., Willis, B. A., Chua, L., Chow, K. H., Ernest, C. S., Shcherbinin, S., Ardayfio, P. A., Mullins, G. R., & Sims, J. R. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2875 · Cited by 98
“Different doses (10– 40 mg/kg, 700, and 1,400 mg) and dosing regimens (single dose, every 2 weeks, and every 4 weeks) were evaluated across the two studies.(2,3) In the investigated dose range, the PKs of donanemab was dose proportional and exhibited timelinear kinetics.”
BackgroundMethodInfluentialSelf-citationComparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology
Therriault, J., Ashton, N. J., Pola, I., Triana-Baltzer, G., Brum, W. S., Di Molfetta, G., Arslan, B., Rahmouni, N., Tissot, C., Servaes, S., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2024.105046 · Cited by 84
Advances in Alzheimer's disease research over the past two decades
Jack, C. R. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00298-8 · Cited by 83
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A.-C. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 84
Lista, S., Imbimbo, B. P., Grasso, M., Fidilio, A., Emanuele, E., Minoretti, P., López-Ortiz, S., Martín-Hernández, J., Gabelle, A., Caruso, G., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03163-y · Cited by 81
“…more recently, with donanemab—a potent anti-Aβ(p3-42) monoclonal antibody—exclusively enrolled patients who, as confirmed by [ 18 F]flortaucipir-PET scans, exhibited pathologic tau deposition (> 1.10 SUVR), but with quantitative tau levels below a specific upper threshold (1.46 SUVR) [151].”
BackgroundInfluentialEarly diagnosis and treatment of Alzheimer’s disease by targeting toxic soluble Aβ oligomers
Habashi, M., Vutla, S., Tripathi, K. K., Senapati, S., Chauhan, P. S., Haviv‐Chesner, A., Richman, M., Mohand, S.-A., Dumulon‐Perreault, V., Mulamreddy, R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210766119 · Cited by 88
“In recent clinical trials, anti-A β antibodies (e.g., Donanemab, Gantenerumab, and Lecanemab) have cleared amyloid plaques and contributed to slowing cognitive decline and memory loss (18, 76–78).”
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease
Rabinovici, G. D., & La Joie, R. (2023) · JAMA · doi:10.1001/jama.2023.11703 · Cited by 80
Iaccarino, L., Burnham, S. C., Dell’Agnello, G., Dowsett, S. A., & Epelbaum, S. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.43 · Cited by 113
“Recent ATT trials, including the donanemab TRAILBLAZER study (8), the aducanumab EMERGE and ENGAGE studies (9), the lecanemab CLARITY AD study (10), and the gantenerumab GRADUATE studies (11) have generally required biomarker confirmation of AD pathology prior to treatment initiation; this helps ensure the study popul…”
BackgroundLoeffler, D. A. (2023) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-230025 · Cited by 79
Dual role of nitric oxide in Alzheimer's disease
Azargoonjahromi, A. (2023) · Nitric Oxide · doi:10.1016/j.niox.2023.03.003 · Cited by 77
The therapeutic landscape of tauopathies: challenges and prospects
Cummings, J. L., González, M. I., Pritchard, M. C., May, P. C., Toledo, L. M., & Harris, G. A. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01321-7 · Cited by 93
“Currently, [18F]flortaucipir (Tauvid ™ ) is the only FDA-approved compound used to monitor tau burden in the brains of AD patients [55].”
BackgroundCummings, J. L. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00570 · Cited by 94
“This relationship was observed in the aducanumab EMRGE trial [29], the lecanemab Phase 2 and Phase 3 trials [30,31], and the donanemab Phase 2 and Phase 3 trials [34,46].”
Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R. P., Amuiri, A. N., Zeltzer, E., Windon, C., Soleimani‐Meigooni, D. N., Tanner, J. A., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13453 · Cited by 89
“Few data have been published on the efficacy of anti-amyloid drugs in EOAD, but exploratory analyses in the lecanemab trial suggested that youngerpatientsmightshowlessclinicalbenefitthanolderpatients.”
BackgroundSelf-citationRabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268756 · Cited by 90
“…maintained throughout the trials, in TRAILBLAZER-ALZ2 (and its phase 2 predecessor TRAIL-BLAZER-ALZ), the duration of antibody treatment was titrated to amyloid PET response, with patients switched from active treatment to placebo after their amyloid PET scans were in the negative range ( 16,235 ).”
Self-citationNoh, M., Kwon, H. S., Kwon, M., Nahm, M., Jin, H. K., Bae, J., & Kim, S. H. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00867-4 · Cited by 97
“…s t r a t e t h e e ff e c t o f a m e d i c a l p r o d u c t C A ‑ 125 i n o v a r i a n c a n c e r [ 236 , 237 ] P G R N * [ 222 ] C T S B * [ 238 , 239 ] S P M s * [ 99 , 101 , 240 ] C D 33 * [ 241 ] I L ‑ 8 , M C P ‑ 1 * [ 242 , 243 ] A m y l o i d P E T [ 244 , 245 ] T a u P E T [ 244 ] α -”
Chowdhury, S., & Chowdhury, N. S. (2023) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320231209839 · Cited by 76
“The success of lecanemab in delaying decline is commendable, especially when coupled with fi ndings from a Phase 2 trial of donanemab, 13 another anti-amyloid immunotherapy.”
BackgroundNeuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders
García‐Domínguez, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060417 · Cited by 105
Immunotherapies for Alzheimer’s disease
Golde, T. E., & Levey, A. I. (2023) · Science · doi:10.1126/science.adj9255 · Cited by 66
Kang, C. (2024) · Drugs · doi:10.1007/s40265-024-02087-4 · Cited by 92
“Baseline patient and disease characteristics were generally similar between donanemab and placebo recipients; the mean iADRS scores at baseline were 106.2 and 105.9, respectively [2].”
InfluentialThe approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA
Karlawish, J. H., & Grill, J. D. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00540-6 · Cited by 73
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 90
“Neurologic Donanemab (Pending) Amyloid β Humanized IgG1 Alzheimer’s disease [386] 2nd cycle review NA”
BackgroundEpelbaum, S., Burgos, N., Canney, M., Matthews, D., Houot, M., Santin, M. D., Desseaux, C., Bouchoux, G., Stroer, S., Martin, C., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00981-1 · Cited by 72
“Recent large trial data from anti-amyloid immunotherapies indicates that cognitive improvement likely requires more complete removal of amyloid over a longer period of time [9, 53].”
BackgroundBelder, C. R. S., Boche, D., Nicoll, J. A. R., Jaunmuktane, Z., Zetterberg, H., Schott, J. M., Barkhof, F., & Fox, N. C. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00335-1 · Cited by 85
Melchiorri, D., Merlo, S., Micallef, B., Borg, J.-J., & Dráfi, F. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1196413 · Cited by 70
“Further data, supporting the clinical benefit of decreasing the Aβ burden in the AD brain are provided by the results of the phase 2 trial of the monoclonal antibody donanemab, targeting a pyroglutamate form of Aβ that is aggregated in amyloid plaques (Mintun et al., 2021; Gueorguieva et al., 2023).”
BackgroundMorris, J. C., Weiner, M., Xiong, C., Beckett, L., Coble, D., Saito, N., Aisen, P. S., Allegri, R., Benzinger, T. L. S., Berman, S. B., et al. (2022) · Brain · doi:10.1093/brain/awac181 · Cited by 68
Self-citationPrecision Medicine Approach to Alzheimer’s Disease: Successful Pilot Project
Toups, K., Hathaway, A., Gordon, D., Chung, H., Raji, C. A., Boyd, A., Hill, B. D., Hausman-Cohen, S., Attarha, M., Chwa, W. J., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215707 · Cited by 85
“The dominant theory over the past three decades has been the amyloid cascade hypothesis [31], but numerous antibodies targeting the associated amyloid have failed to improve cognition (although a recent trial that failed to improve cognition or halt decline nevertheless slowed decline by 32% [2]).”
BackgroundModified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Wang, H., Nery, E. S. M., Ardayfio, P. A., Khanna, R., Svaldi, D. O., Gueorguieva, I., Shcherbinin, S., Andersen, S. W., Hauck, P. M., Engle, S. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70062 · Cited by 89
“2,4,5 Therefore, the timing and dosage of initial infusions are important considerations in ARIA-E reduction.”
InfluentialSelf-citationAlzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 75
Sex differences in longitudinal tau-PET in preclinical Alzheimer disease: a meta-analysis
Coughlan, G. T., Klinger, H. M., Boyle, R., Betthauser, T. J., Binette, A. P., Christenson, L., Chadwick, T., Hansson, O., Harrison, T. M., Healy, B., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0013 · Cited by 69
Considerations regarding a diagnosis of Alzheimer’s disease before dementia: a systematic review
van der Schaar, J., Visser, L. N. C., Bouwman, F. H., Ket, J. C. F., Scheltens, P., Bredenoord, A. L., & van der Flier, W. M. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00971-3 · Cited by 83
Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
Nunes, D., Loureiro, J. A., & Pereira, M. C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112296 · Cited by 68
Aducanumab: a new phase in therapeutic development for Alzheimer’s disease?
Lalli, G., Schott, J. M., Hardy, J., & De Strooper, B. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114781 · Cited by 67
“…plaques (Cummings et al, 2019); and indeed, promising results from phase II clinical trials with other anti-Ab monoclonal antibodies, including gantenerumab (Klein et al, 2019), lecanemab (Swanson et al, 2021) and more recently donanemab (Mintun et al, 2021) have led to ongoing phase III studies.”
BackgroundMüller cell degeneration and microglial dysfunction in the Alzheimer’s retina
Xu, Q., Boerkoel, P., Hirsch‐Reinshagen, V., Mackenzie, I. R., Hsiung, G. R., Charm, G., To, E., Liu, A., Schwab, K. D., Jiang, K., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01448-y · Cited by 68
“Although AD was first described more than 100 years ago, even current cutting edge therapeutics such as Donanemab have failed to impact secondary outcomes such as cognition and severity of dementia, despite slowed decline measured by the Integrated Alzheimer’s Disease Rating Scale [2, 43, 54].”
MethodLiang, Y., Liu, C., Cheng, M., Geng, L., Li, J., Du, W., Song, M., Chen, N., Yeleen, T. A. N., Li, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14057 · Cited by 83
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
Imbimbo, B. P., Ippati, S., Watling, M., & Imbimbo, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106631 · Cited by 65
Formolo, D. A., Yu, J., Lin, K., Tsang, H. W. H., Ou, H., Kranz, G. S., & Yau, S. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00618-3 · Cited by 78
“has fostered the development of anti-amyloid agents [103–105], leading to the FDA approval of the monoclonal antibody Aducanumab [106] and, more recently, the Lecanemab [107], while other antibody-based interventions, such as the Gantenerumab [108], are likely to be approved soon [104, 105].”
BackgroundKhoury, N., Pizzo, M. E., Discenza, C. B., Joy, D. A., Tatarakis, D., Todorov, M. I., Negwer, M., Ha, C., de Melo, G. L., Sarrafha, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57108-x · Cited by 84
rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data
Iaccarino, L., La Joie, R., Koeppe, R., Siegel, B. A., Hillner, B. E., Gatsonis, C., Whitmer, R. A., Carrillo, M. C., Apgar, C., Camacho, M. R., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2021.118775 · Cited by 64
“PET quantification may in the future be used to gauge treatment response or manage dose titration and treatment duration, as was done in a recent Phase 2 study of the anti-amyloid antibody donanemab (Mintun et al., 2021).”
Current clinical investigations of focused ultrasound blood-brain barrier disruption: A review
Durham, P. G., Butnariu, A., Alghorazi, R., Pinton, G., Krishna, V., & Dayton, P. A. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00352 · Cited by 62
Groot, C., Smith, R. A., Collij, L. E., Mastenbroek, S. E., Stomrud, E., Binette, A. P., Leuzy, A., Palmqvist, S., Mattsson, N., Strandberg, O. T., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1612 · Cited by 78
Kang, J. H., Korecka, M., Lee, E. B., Cousins, K. A. Q., Tropea, T. F., Chen-Plotkin, A. A., Irwin, D. J., Wolk, D., Brylska, M., Wan, Y., et al. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad139 · Cited by 64
Poewe, W., on behalf of the AFF011 investigators, AFF011 study investigators:, Volc, D., Seppi, K., Medori, R., Lührs, P., Kutzelnigg, A., Djamshidian, A., Thun-Hohenstein, C., et al. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212594 · Cited by 77
The complex pathway between amyloid β and cognition: implications for therapy
Jagust, W. J., Teunissen, C. E., & DeCarli, C. S. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00128-x · Cited by 75
Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease
Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022) · Neuronal Signaling · doi:10.1042/ns20210004 · Cited by 60
Coley, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease
Ossenkoppele, R., & Hansson, O. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12356 · Cited by 62
Han, Y., Chen, R., Lin, Q., Liu, Y., Ge, W., Cao, H., & Li, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16855 · Cited by 67
Yin, H., Ju, Z., Zheng, M., Zhang, X., Zuo, W., Wang, Y., Ding, X., Zhang, X., Peng, Y., Li, J., et al. (2023) · PLOS Biology · doi:10.1371/journal.pbio.3002017 · Cited by 62
“At present, some clinical trials targeting Aβ are investigated for the treatment of early AD [54,55].”
BackgroundPassive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
“Treatment with donanemab reduced mean amyloid plaque levels from 107.6 CL baseline to 22.54 CL and resulted in amyloid negativity in 67.8% of patients (Mintun et al., 2021).”
InfluentialKarlsson, L., Vogel, J. W., Arvidsson, I., Åström, K., Janelidze, S., Blennow, K., Palmqvist, S., Stomrud, E., Mattsson, N., & Hansson, O. (2024) · Nature Communications · doi:10.1038/s41467-024-47971-5 · Cited by 69
Imbimbo, B. P., Balducci, C., Ippati, S., & Watling, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.340409 · Cited by 77
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 67
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research
Iaccarino, L., Burnham, S., Tunali, I., Wang, J., Navitsky, M., Arora, A., & Pontecorvo, M. (2025) · NeuroImage: Clinical · doi:10.1016/j.nicl.2025.103765 · Cited by 66
“…referred to therapeutic studies with ATTs (i.e., aducanumab (two studies reported in Budd Haeberlein et al., 2022), donanemab (Lowe et al., 2021; Mintun et al., 2021; Sims et al., 2023), gantenerumab (two studies reported in Bateman et al., 2023; Boess et al., 2022; Chen et al., 2023; Klein et…”
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 89
“Plaque reduction on PET can be demonstrated after 6 months or less exposure with some agents 141 .”
InfluentialAlkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“Reductions in plasma p-tau_217_ and GFAP in donanemab-treated patients correlated with the degree of A β clearance [155,156], reinforcing that these drugs engage the disease biology.”
Madhav, H., Jameel, E., Rehan, M., & Hoda, N. (2022) · RSC Medicinal Chemistry · doi:10.1039/d1md00394a · Cited by 65
Metadata
- Authors
- Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., Apostolova, L. G., Salloway, S. P., & Skovronsky, D. M.
- Affiliations
- Eli Lilly (United States) (US)
- From Eli Lilly (M.A.M., A.C.L., C.D.E., A.M.W., P.A.A., S.W.A., S.S., J.S., J.R.S., M.B., D.M.S.) and the Departments of Neurology, of Radiology and Imaging Sciences, and of Medical and Molecular Genetics and the Indiana Alzheimer Disease Center, Indiana University School of Medicine (L.G.A.) — both in Indianapolis; and the Departments of Psychiatry and Human Behavior and of Neurology, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI (S.P.S.).
- Brown University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-05-06
- Volume
- 384
- Issue
- 18
- Pages
- 1691-1704
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137826907
- Cited by
- 1,728
- References
- 39
- Citations by year
- 2026: 302 · 2025: 409 · 2024: 369 · 2023: 271 · 2022: 263 · 2021: 112
- FWCI
- 160.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- donanemab, early Alzheimer's disease, amyloid-beta, anti-amyloid antibodies, amyloid plaques, tau burden, activities of daily living, cognitive decline
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Alzheimer Disease, Epitopes, Brain Edema, Cognition, Double-Blind Method, Female, Humans, Male, Pyrrolidonecarboxylic Acid, Severity of Illness Index, Disease Progression, Plaque, Amyloid, Administration, Intravenous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.